下步，区发展和改革局将持续加强各类创新平台的培育与监管，进一步推动科技成果转化为新质生产 力，助力全区现代化建设迈向新台阶。(烟台市牟平区发展和改革局王祯) 中国发展网讯近日，山东省烟台市发展和改革委员会发布了《关于公布2025年新认定烟台市工程研究中 心名单的通知》，经烟台市牟平区发展和改革局积极谋划、全力争取，山东佰鸿干细胞生物技术有限公 司的"干细胞新药研制与转化应用工程研究中心"项目成功入选。 烟台市牟平区发展和改革局始终高度重视创新平台培育工作，积极指导企业规范申报、精准对接，全力 服务项目入围。此次入选体现了该区在生物医药方面的科研转化能力不断增强，对推动产业技术进步、 提升核心竞争力具有重要意义。 ...

Core Viewpoint - The article highlights the challenges faced by biopharmaceutical companies in Shenzhen regarding the approval of production licenses for standalone factory buildings, emphasizing the need for clearer regulations to support the industry's growth [1][2][3]. Group 1: Industry Challenges - Biopharmaceutical companies are struggling to find suitable standalone factory buildings of approximately 7,000 square meters for the commercialization of new stem cell drugs [1]. - The "industrial building up" policy in Shenzhen has not significantly benefited pharmaceutical companies, as they require standalone buildings to obtain production licenses [1]. - Many companies face a dilemma between choosing standalone buildings, which are more likely to receive production licenses but are often too large for their needs, and opting for "industrial building up," which carries the risk of not obtaining the necessary licenses [1]. Group 2: Regulatory Environment - The Guangdong Provincial Drug Administration has introduced a "one enterprise, one policy" approach to improve service for companies, but many firms find the limited successful cases of "industrial building up" to be of little reference value [2]. - The lack of clear and transparent rules creates uncertainty for biopharmaceutical companies, which are particularly vulnerable during their early stages of development [2]. - There is a call for the establishment of explicit rules for biopharmaceutical companies to alleviate the anxiety surrounding the approval process and to foster a more predictable regulatory environment [3].